Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Filamon Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, ESPINOSA, CLAUDIA EDILMA. The portfolio is located in 1 distinct art unit. ESPINOSA, CLAUDIA EDILMA serves as the busiest examiner for the company with 1 pending action.
The prosecution strategy for the Biotechnology & Pharmaceuticals matter depends on the interaction with the 1 distinct examiner. Practitioners should focus on the requirements of the assigned personnel to navigate the process. The 1 distinct art unit contains the entirety of the company's current pending work. Every development in the case is critical to the intellectual property position. The results of the 1 pending office action will determine the immediate direction of development in this field. Practitioners can use the examiner's history to anticipate potential challenges during the prosecution.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ESPINOSA, CLAUDIA EDILMA | 1 | 50.9% | +57.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19355164 | EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | ESPINOSA, CLAUDIA EDILMA | 22d |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19355164 | EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | ESPINOSA, CLAUDIA EDILMA | 1654 | §102 | Non-Final OA | 22d | Pending | Oct 10, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial